Abstract
Twenty patients have received 21 courses of high-dose cyclophosphamide (6 g/m2 over 4 days), etoposide (1,800 mg/m2 over 3 days), and carboplatin (800 to 1,600 mg/m2 by continuous infusion over 96 hours) and autologous bone marrow or peripheral blood stem cell rescue. The maximum tolerated dose of this regimen included these doses of cyclophosphamide and etoposide with a total of 1,600 mg/m2 carboplatin. Acute renal failure was the dose-limiting toxicity and, at the maximum tolerated dose, was observed in two patients of 14 evaluable courses. Nonhematologic toxicity was otherwise modest, and the overall response rate was 70% in patients with a wide variety of solid hematologic neoplasms.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Kidney Injury / chemically induced
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Blood Component Transfusion*
-
Bone Marrow Transplantation*
-
Candidiasis / etiology
-
Carboplatin / administration & dosage*
-
Carboplatin / adverse effects
-
Clinical Trials, Phase I as Topic
-
Cyclophosphamide / administration & dosage*
-
Cyclophosphamide / adverse effects
-
Etoposide / administration & dosage*
-
Etoposide / adverse effects
-
Female
-
Humans
-
Infusions, Intravenous
-
Male
-
Neutropenia / chemically induced
-
Remission Induction
-
Stem Cells / pathology
-
Survival Rate
-
Thrombocytopenia / chemically induced
Substances
-
Etoposide
-
Cyclophosphamide
-
Carboplatin